Display Settings:

Format

Send to:

Choose Destination
J Glob Infect Dis. 2010 May;2(2):159-66. doi: 10.4103/0974-777X.62886.

Liposomal amphotericin B and leishmaniasis: dose and response.

Author information

  • 1Department of Medicine, Institute of Medical Sciences, Banaras Hindu University, Varanasi - 221 005, India.

Abstract

Liposomal amphotericin B has been used with increasing frequency to treat visceral leishmaniasis (VL). It is the treatment of choice for immunocompetent patients in the Mediterranean region and the preferred drug for HIV/VL co-infection. Although there is a regional variation in the susceptibility of the parasite a total dose of 20 mg/kg is effective in immunocompetent patients. Randomized clinical trials of liposomal amphotericin B in the treatment and secondary prophylaxis of HIV-VL coinfected patients is urgently needed to optimize treatment in this subset. With the availability of Liposomal amphotericin B at a preferential pricing in the endemic areas, short course combination therapy can become a viable alternative.

KEYWORDS:

Amphotericin B; Kala-azar; Liposomal

PMID:
20606972
[PubMed]
PMCID:
PMC2889656
Free PMC Article
PubMed Commons home

PubMed Commons

0 comments
How to join PubMed Commons

    Supplemental Content

    Full text links

    Icon for Medknow Publications and Media Pvt Ltd Icon for PubMed Central
    Loading ...
    Write to the Help Desk